新辅助化疗在乳腺浸润性小叶癌与浸润性导管癌患者的应用

Application of neoadjuvant chemotherapy in patient with invasive lobular carcinoma and invasive ductal carcinoma

目的探讨新辅助化疗(NAC)在乳腺浸润性小叶癌(ILC)和浸润性导管癌(IDC)患者的应用。方法选取诊断为乳腺癌并接受NAC治疗的患者109例;其中,ILC患者42例(A组),IDC患者67例(B组)。比较两组接受NAC治疗后的有效率、病理完全缓解率及保乳率。结果NAC治疗后,B组治疗有效率高于A组(83.6%vs.81.0%)(P<0.05)。A组患者在接受NAC治疗后达到病理完全缓解率高于B组(19.0%vs.16.4%)(P<0.05)。NAC治疗后,A组保乳率低于B组(42.9%vs.47.8%)(P<0.05)。结论NAC治疗后IDC患者较ILC患者有效率高、保乳率高,但病理完全缓解率低。

Objective To explore the application of neoadjuvant chemotherapy(NAC)in the patients with invasive lobular carcinoma(ILC)and invasive ductal carcinoma(IDC).Methods A total of 109 breast cancer patients was diagnosed as ILC in 42 cases(group A)and IDC in 67 cases(group B),who were all treated with NAC before surgery.The effectiveness rate,pathological complete remission rate and breast-conserving rate were compared between the two groups.Results After NAC treatment,the effectiveness rate of group B was higher than that of group A(83.6%vs.81.0%)(P<0.05)and the rate of pathological complete response in group A was higher than that in group B(19.0%vs.16.4%)(P<0.05).The breast-conserving rate of group A was lower than that of group B(42.9%vs.47.8%)(P<0.05).Conclusion After NAC treatment,IDC patients have higher efficiency and higher breast-conserving rate than ILC patients,but the pathological complete remission rate of IDC patients is lower than that of ILC patients.